Bunkerhill Health
Get twice-weekly insights on the biggest stories shaping cardiology.
You might also like
Surgeries & Interventions May 22, 2025
Navitor Versus Sapien 3 Ultra: Different in the Details May 22, 2025
One year data from the NAVULTRA study published in JACC suggests that Edwards’ Sapien 3 Ultra and Abbott’s Navitor intra-annular TAVR valves have similar short-term clinical outcomes, with a few key differences. The NAVULTRA study explored data from 4k TAVR patients who received either Navitor or Sapien 3 Ultra and found that all-cause mortality was […]
Cardiology Pharmaceuticals May 19, 2025
Wegovy Rapidly Lowers MACE Risk May 19, 2025
Getting us closer to understanding GLP-1s’ heart benefits, a post hoc analysis of the SELECT trial suggests that Novo Nordisk’s Wegovy (semaglutide) significantly reduces a patient’s MACE risk in just three months of treatment. Researchers analyzed the SELECT trial data by looking at CV events in the first three to six months following semaglutide treatment […]
Cardiology Pharmaceuticals May 15, 2025
Tirzepatide Beats Semaglutide in Weight Loss May 15, 2025
Has a king of the GLP-1s finally been crowned? Full results from the SURMOUNT-5 trial published in NEJM seem to suggest that Eli Lilly’s tirzepatide (Zepbound/Mounjarno) could be better than Novo Nordisk’s semaglutide (Wegovy/Ozempic). Weighing the weight loss benefits of each drug, SURMOUNT-5’s researchers randomized 751 obese patients without T2D to receive either tirzepatide (10mg/15mg) […]
